Dr. John M. O’Brien Joins Sempre Board of Directors

Sempre Health welcomes Dr. John M. O’Brien, a recognized leader in health policy and pharmaceutical innovation, to its Board of Directors.

By: Anurati Mathur, Co-Founder & CEO at Sempre Health

I’m thrilled to welcome Dr. John O’Brien to Sempre Health’s Board of Directors.

Dr. John M. O’Brien, PharmD, MPH, brings an extraordinary breadth of expertise spanning the life sciences, managed care, academia, and government. He is President and Chief Executive Officer of the National Pharmaceutical Council, which advances policy-relevant research on the value of patient access to innovative medicines and the importance of scientific advancement. He has held senior leadership roles at CareFirst BlueCross BlueShield, served as Senior Advisor at the Centers for Medicare & Medicaid Services (CMS), and held a number of medical and government affairs roles in the pharmaceutical industry.

What stands out most about Dr. O’Brien is his unwavering commitment to patients, a value that sits at the core of everything we do at Sempre Health. To date, our programs have helped patients save nearly $40 million on prescriptions through behavior-based affordability models that drive measurable improvements in adherence. His cross-sector insight into how business, policy, and innovation intersect will be invaluable as we continue our mission to make medications more affordable and accessible for patients.

“I am honored to join Sempre Health’s Board of Directors and contribute my experience at the intersection of health policy, drug pricing, and payer strategy,” said Dr. O’Brien. “My career has focused on aligning our healthcare system around patient access and the value of innovative medicines. Sempre Health is bringing a vision of improved affordability, adherence, and patient experience to life.”

As we’ve grown from a startup with a bold vision to a proven solution delivering real savings and tested outcomes, having a leader of Dr. O’Brien’s caliber strengthens our commitment to closing the gap between innovation and tangible patient outcomes.

We’re grateful for Dr. O’Brien’s leadership and excited for the strategic guidance he’ll bring as we work toward a future where everyone can access the medications they need.